mechanism of action of glp-1 receptor agonists Current Insights, Advantages and Challenges Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review Glucagon-Like Peptide-1 Receptor Agonists And
Description
doi: 10.3389/fnins.2022.970925

Comorbidities in recent-onset adult type 1 diabetes: a comparison of German cohorts
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1

As mentioned by Lingvay et al., semaglutide has shown promise as a treatment option for non-diabetics with established atherosclerotic disease by reducing their risk of MACE by 20% despite having varying HBA1c baselines [47]
